These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 14673623

  • 1. CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid.
    Bornhauser M, Jenke A, Freiberg-Richter J, Radke J, Schuler US, Mohr B, Ehninger G, Schleyer E.
    Ann Hematol; 2004 Jun; 83(6):401-2. PubMed ID: 14673623
    [Abstract] [Full Text] [Related]

  • 2. Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases.
    Higashi T, Tsukada J, Kato C, Iwashige A, Mizobe T, Machida S, Morimoto H, Ogawa R, Toda Y, Tanaka Y.
    Am J Hematol; 2004 Jul; 76(3):275-8. PubMed ID: 15224366
    [Abstract] [Full Text] [Related]

  • 3. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC, Zheng D, Li QH, Li XH, Cai CC, Luo SK, Li J, Peng AH, Tong XZ, Tan EX, Hong WD.
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [Abstract] [Full Text] [Related]

  • 4. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
    Palandri F, Castagnetti F, Testoni N, Luatti S, Marzocchi G, Bassi S, Breccia M, Alimena G, Pungolino E, Rege-Cambrin G, Varaldo R, Miglino M, Specchia G, Zuffa E, Ferrara F, Bocchia M, Saglio G, Pane F, Alberti D, Martinelli G, Baccarani M, Rosti G, GIMEMA Working Party on Chronic Myeloid Leukemia.
    Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
    [Abstract] [Full Text] [Related]

  • 5. Isolated central nervous system blast crisis in chronic myeloid leukemia.
    Rajappa S, Uppin SG, Raghunadharao D, Rao IS, Surath A.
    Hematol Oncol; 2004 Dec; 22(4):179-81. PubMed ID: 15995975
    [Abstract] [Full Text] [Related]

  • 6. Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation.
    Wassmann B, Scheuring U, Thiede C, Pfeifer H, Bornhäuser M, Griesinger F, Hochhaus A, Schleyer E, Gschaidmeier H, Hoelzer D, Ottmann OG.
    Bone Marrow Transplant; 2003 Apr; 31(7):611-4. PubMed ID: 12692630
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.
    Pfeifer H, Wassmann B, Hofmann WK, Komor M, Scheuring U, Brück P, Binckebanck A, Schleyer E, Gökbuget N, Wolff T, Lübbert M, Leimer L, Gschaidmeier H, Hoelzer D, Ottmann OG.
    Clin Cancer Res; 2003 Oct 15; 9(13):4674-81. PubMed ID: 14581336
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy.
    Alimena G, Breccia M, Latagliata R, Carmosino I, Russo E, Biondo F, Diverio D, Mancini M, Nanni M, Mandelli F.
    Cancer; 2006 Sep 01; 107(5):1008-13. PubMed ID: 16878324
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate.
    Matsuda M, Morita Y, Shimada T, Miyatake J, Hirase C, Tanaka M, Tatsumi Y, Maeda Y, Kanamaru A.
    Int J Hematol; 2005 May 01; 81(4):307-9. PubMed ID: 15914360
    [Abstract] [Full Text] [Related]

  • 13. [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].
    Liu XL, Zhou SY, Du QF, Zheng WY, Zhang S, Song LL, Xu B, Liu QF, Meng FY.
    Ai Zheng; 2004 Apr 01; 23(4):421-5. PubMed ID: 15087031
    [Abstract] [Full Text] [Related]

  • 14. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
    Lahaye T, Riehm B, Berger U, Paschka P, Müller MC, Kreil S, Merx K, Schwindel U, Schoch C, Hehlmann R, Hochhaus A.
    Cancer; 2005 Apr 15; 103(8):1659-69. PubMed ID: 15747376
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Isolated central nervous system relapse after nine years of complete molecular remission in a lymphoid blast crisis of chronic myeloid leukemia treated with imatinib.
    Breccia M, Santopietro M, Cannella L, Federico V, Loglisci G, Serrao A, Petrucci L, Salaroli A, Nanni M, De Propris MS, Diverio D, Alimena G.
    Leuk Res; 2011 Jun 15; 35(6):e91-2. PubMed ID: 21316103
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
    DeAngelo DJ, Hochberg EP, Alyea EP, Longtine J, Lee S, Galinsky I, Parekkedon B, Ritz J, Antin JH, Stone RM, Soiffer RJ.
    Clin Cancer Res; 2004 Aug 01; 10(15):5065-71. PubMed ID: 15297408
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.